Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Montemurro

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2011
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancerS Gori, F Montemurro, S Spazzapan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2007
Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating studyA Sapino, F Montemurro, C Marchiò, et al.
ESMO Open|September 9, 2022
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancerR Wuerstlein, P Ellis, F Montemurro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2016
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)G Jerusalem, G Mariani, E M Ciruelos, et al.
ESMO Open|January 22, 2025
Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real worldE Blondeaux, L Boni, G Chilà, et al.
ESMO Open|January 5, 2021
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)B Pellegrino, L Cavanna, D Boggiani, et al.
ESMO Open|April 5, 2021
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyF Schettini, B Conte, G Buono, et al.
Breast Cancer Research and Treatment|November 15, 2014
Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional studyD Balmativola, C Marchiò, M Maule, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2011
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancerS Gori, F Montemurro, S Spazzapan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2007
Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating studyA Sapino, F Montemurro, C Marchiò, et al.
ESMO Open|September 9, 2022
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancerR Wuerstlein, P Ellis, F Montemurro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2016
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)G Jerusalem, G Mariani, E M Ciruelos, et al.
ESMO Open|January 22, 2025
Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real worldE Blondeaux, L Boni, G Chilà, et al.
ESMO Open|January 5, 2021
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)B Pellegrino, L Cavanna, D Boggiani, et al.
ESMO Open|April 5, 2021
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyF Schettini, B Conte, G Buono, et al.
Breast Cancer Research and Treatment|November 15, 2014
Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional studyD Balmativola, C Marchiò, M Maule, et al.
Pageof 4